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A B S T R A C T
Allogeneic hematopoietic cell transplantation (HCT) can halt organ damage and eliminate symptoms in he-
moglobin disorders, including sickle cell disease (SCD) and thalassemia major. Managing the residual
manifestations of pre-HCT disease complications and the long-term effects of HCT requires systematic moni-
toring, follow-up and intervention when indicated. Late complications vary with age and disease status at
HCT and with transplant variables such as preparative regimen, donor source and compatibility, and immune
reconstitution. An international consensus conference sponsored by the Pediatric Blood and Marrow Trans-
plant Consortium inMay 2016 entitled “Late Effects Screening and Recommendations Following HCT for Immune
Deﬁciency and Nonmalignant Hematologic Disorders” focused on follow-up after HCT for hemoglobinopa-
thy. An earlier publication from experts who participated in this session described the pathophysiology and
spectrum of complications that HCT recipients experience after HCT for SCD and thalassemia major. This com-
panion publication summarizes the consensus reached by this group of experts about long-term follow-up
guidelines after HCT for hemoglobinopathy. In addition, these guidelines might also be included in studies
of novel curative therapies such as autologous HCT after hematopoietic progenitor stem cell gene modiﬁcation.
© 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights
reserved.
INTRODUCTION
Hematopoietic cell transplantation (HCT) is indicated for
symptomatic hemoglobinopathy and can provide a cure. The
most common hemoglobin disorders treated by HCT are
transfusion-dependent thalassemia major and sickle cell
disease (SCD). The number of patients, predominantly chil-
dren, undergoing HCT for hemoglobinopathy is increasing each
year and has a worldwide distribution. This has resulted in
an expanding number of HCT survivors cured of their disease
with an extended number of years of life without symp-
toms gained after the transplant intervention, in most cases.
These patients should have optimized long-term healthcare
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monitoring to ensure post-transplant well-being, so that late
complications can be recognized promptly and treated or sup-
ported early.
A conference sponsored by the Pediatric Blood andMarrow
Transplant Consortium in May 2016 focused on long-term
follow-up after HCT in nonmalignant disorders and in-
cluded a session for hemoglobinopathies [1]. The key aims
of this meeting of international experts in the ﬁeld were to
summarize current knowledge regarding late effects and
disease-related outcomes after HCT for hemoglobinopa-
thies, identify gaps in uniformity of long-term follow-up
after transplant, describe areas of future research, and
develop guidelines to aid in standardized screening and
monitoring after HCT. In a previous publication this group
reviewed existing data on survival and follow-up after HCT
for hemoglobinopathies [2]. In this article we summarize
our recommendations aboutmonitoring after HCT and provide
roadmaps for longitudinal evaluation based on unique disease-
and transplant-related features. The goal is to focus on
conducting comprehensive follow-up after HCT, high-
lighted by medical need and by areas for improvement,
thus promoting new investigation in this ﬁeld. Further,
these recommendations can be adapted for future trans-
plant and gene modiﬁcation trials, follow-up protocols, or
long-term registries as appropriate and can be used as
standard medical care by providers and in survivorship
programs.
Late effects after HCT are inﬂuenced by recipient age at
transplant, disease status and pre-existing comorbidities,
transplant method and conditioning regimen, donor source,
HLA compatibility, post- transplant complications, and
immune reconstitution. Avoidance of complications andmor-
tality caused by the underlying disease or the transplant itself
requires anticipation, early recognition, and adequate medical
support [3-5]. There are also focus points of risk to recog-
nize and mitigate when designing a clinical trial for these
disorders.
Based on current knowledge about long-term follow-up
in hemoglobinopathy patients, the areas beneﬁtted by sys-
tematic follow-up after HCT and have research value include
the following:
• Deﬁning transplant outcomes in relation to recipient age,
disease status, donor sources, and transplant methods to
identify areas for improvement
• Tracking engraftment to ensure stable mixed or full donor
chimerism
• Minimizing transplant-related complications such as mor-
tality, graft-versus-host disease, (GVHD), and delayed
immune reconstitution
• Deﬁning strategies to evaluate and reduce iron overload
• Organ function monitoring, including cardiopulmonary,
liver, and kidney functions
• Monitoring central nervous system (CNS) outcomes and
neurocognitive function after posterior reversible en-
cephalopathy syndrome episodes, cerebral vasculopathy
including moyamoya disease, cerebral atrophy, and hem-
orrhagic or ischemic lesions in the brain
• Endocrine organ function monitoring of thyroid and
gonadal function, linked to growth and pubertal
development/fertility
• Assessment of pain and pain control post-HCT including
opioid use
• Quality of life assessment, education, employment
• Healthcare utilization before, during, and after HCT
These surveillance guidelines take into consideration the
prioritized factors, listed above, that determine the success
of HCT as a curative intervention.
Donor characteristics also might affect follow-up plan-
ning after HCT for hemoglobinopathies. These considerations
include not only the source of donor cells but also other
genetic characteristics. For example, if a donor had thalas-
semia or sickle trait, recipient follow-up should consider trait
modiﬁers. If the donor had glucose-6-phosphate dehydro-
genase enzyme deﬁciency, the recipient might beneﬁt from
counseling about this condition. However, neither condi-
tion is a contraindication to stem cell donation in a patient
with hemoglobinopathy [6,7].
FOLLOW-UP RECOMMENDATIONS AFTER HCT FOR
THALASSEMIA
After HCT for transfusion-dependent thalassemia, there
is a risk of chronic anemia in the absence of optimal man-
agement, complications of iron overload and its treatment,
and RBC allo-immunization [8]. Transfusion-related infec-
tions have declined after adopting modern blood screening
procedures, especially in developed countries. Monitoring and
management guidelines post-HCT should take into consid-
eration organ toxicities associated with transfusions and iron
overload such as cardiac, hepatic, and endocrine insuﬃcien-
cy [9-12]. Many manifestations of endocrine function
impairment are multifactorial; iron toxicity, chelation med-
ication toxicity, and HCT regimens are contributing factors.
Impaired glucose tolerance post-transplant in nonmalig-
nant disorders is rare and was previously a consequence of
unfractionated radiation-based conditioning regimens. Hep-
atitis C virus (HCV) infection was common in thalassemia
patients, particularly in those transfused before second-
generation ELISA tests for detecting HCV in donors became
available [13]. The risks of chronic HCV infection persists in
patients with viremia and should be treated with modern an-
tiviral therapy [14,15]. Splenectomized patients will remain
vulnerable to encapsulated bacterial organisms lifelong.
Conditioning regimens with iron overload together may
increase susceptibility to post-transplant hepatic sinusoi-
dal obstruction syndrome early or late onset after HCT. Cardiac
function generally stabilizes after HCT andmay improve after
reducing the cardiac iron burden [16]. Complications related
to iron overload can be effectively prevented post-HCT with
appropriate iron reduction therapy (regular phlebotomy or
iron chelation therapy) and is expected to improve in about
50% of patients depending on age and compliance. Hypogo-
nadism is the most frequent endocrine complication
described; the 2 major risk factors for hypogonadism are iron
overload and conditioning regimens that contain busulfan or
treosulfan. In this setting the incidence of hypogonadism after
HCT before puberty is high (Supplemental Table S1). Approx-
imately 40% of childrenwill experience puberty normally after
HCT despite having clinical and hormonal evidence of hy-
pogonadism [17]. Fertility, however, is better preserved when
HCT is performed in young, prepubertal children, presum-
ably because of the gonadal dormancy and the shorter
duration of exposure to iron overload [18]. The develop-
ment of reduced-toxicity/reduced-intensity regimens might
also attenuate the risk of gonadal damage [19,20]. Table 1 il-
lustrates details on thalassemia-speciﬁc complications and
the long-term follow-up schedule recommended for identi-
ﬁcation of complications and intervention. Although no
pregnancy-related complications have been reported to date,
careful follow-up is nevertheless recommended during
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Table 1
Follow-Up Recommendations after HCT for Thalassemia and SCD
Organ/System Thalassemia SCD
Immune functions
-Lymphocyte
subpopulations
-Lymphocyte
proliferation
-Immunoglobulin
levels
-Vaccine-speciﬁc
antibody titers
• Monitor at 6 months, 1 year, then every 6 months until
immune recovery is complete; include post-vaccination-
speciﬁc antibody titers (tetanus, diphtheria, pneumococcus)
• Immunizations per ASBMT/EBMT
guidelines (http://www.nature.com/bmt/journal/v44/n8/
full/bmt2009263a.html?foxtrotcallback=true)
• Consider antibiotic prophylaxis against encapsulated
organisms until B cell recovery and indeﬁnitely in post-
splenectomy patients
• Pneumocystis jirovecii prophylaxis for 6 months and until
systemic immunosuppression is on a wean in the absence of
cGVHD
• Give fungal prophylaxis until 100 days after HCT; extend
prophylaxis if there is active cGVHD treated by
immunosuppression
• Monitor at 6 months, 1 year, then every 6 months until
immune recovery is complete; include post-vaccination-
speciﬁc antibody titers (tetanus, diphtheria, pneumococcus)
• Immunizations per ASBMT/EBMT
guidelines (http://www.nature.com/bmt/journal/v44/n8/
full/bmt2009263a.html?foxtrotcallback=true)
• Continue PCN prophylaxis until splenic regeneration has
been proved by liver-spleen scan and a normal pitted RBC
score (<1.5%) and vaccination against pneumococcus is
effectively completed.
• Antibiotic prophylaxis against encapsulated organisms until
B cell recovery and indeﬁnitely in postsplenectomy patients
• Pneumocystis jirovecii prophylaxis for 6 months and until
systemic immunosuppression is on a wean in the absence of
cGVHD
• Give fungal prophylaxis until 100 days after HCT; extend
prophylaxis if there is active cGVHD treated by
immunosuppression
Iron overload • Assess iron load with serum ferritin and transferrin
saturation every 3-6 months commencing 6 months after
HCT* until normal
• If abnormal, start iron depletion with phlebotomy or iron
chelation ideally after stopping or reducing systemic
immunosuppression. Discontinue iron reduction therapy
when iron stores (serum ferritin and transferrin
saturation) are in the normal range
• Avoid concomitant use of deferasirox and calcineurin
inhibitors due to risk of nephrotoxicity
• Compare T2* MRI at 1 year with pre-HCT evaluation to
document stability/improvement
• If T2* MRI is abnormal continue iron depletion or chelation
until normalized
• Assess iron load with serum ferritin and transferrin
saturation every 3-6 months commencing 6 months after
HCT* until normal
• If consistently abnormal, start iron depletion with
phlebotomy or iron chelation ideally after stopping or
reducing systemic immunosuppression. Discontinue iron
reduction therapy when iron stores (serum ferritin and
transferrin saturation) are in the normal range
• Avoid concomitant use of deferasirox and calcineurin
inhibitors due to risk of nephrotoxicity
• If T2* MRI is abnormal continue iron depletion or chelation
until normalized
Heart • Consider cardiac iron by T2* MRI at 1 year after HCT in
patients with moderate or severe iron overload before HCT
• Echocardiogram annually for 5 years after HCT or longer if
indicated
• If T2* value is 10-20 ms (moderate iron overload) continue
standard chelation/phlebotomy until normalized
• If T2* < 10 ms (severe iron overload) commence intensive
parenteral iron chelation therapy with continuous i.v.
desferrioxamine until T2* > 20 ms
• Consider lipid proﬁle at 1 year, continue annually for 5 years
or as clinically indicated
• Monitor blood pressure annually
• Consider cardiac iron by T2* MRI at 1 year after HCT in
patients with moderate or severe iron overload at HCT
• Echocardiogram annually for 5 years after HCT or longer if
indicated
• If T2* value is 10-20 ms (moderate iron overload) continue
standard chelation/phlebotomy until normalized
• If T2* < 10 ms (severe iron overload) commence intensive
parenteral iron chelation therapy with continuous i.v.
desferrioxamine until T2* > 20 ms
• Consider lipid proﬁle at 1 year, continue annually for 5 years
or as clinically indicated
• Monitor blood pressure annually
Liver • Assess liver function tests every month through 1 year after
HCT, every 3 months in year 2, and then as clinically
indicated (such as cGVHD or hepatitis). Include albumin,
GGT, and PT evaluation. Include ammonia level if indicated.
• Consider liver biopsy at 2 years after transplantation in
patients who had bridging ﬁbrosis before transplantation
• Consider liver biopsy at 2 years for patients who had
hepatitis B (HBAg positive) or HCV before transplantation
• Refer patients who have HCV/hepatitis B infection to
gastroenterologist/infectious disease specialist for
consideration of antiviral therapy
• Assess liver function tests every month through 1 year
after HCT, every 3 months in year 2, and then as clinically
indicated (such as cGVHD or hepatitis). Include albumin,
GGT, and PT evaluation. Include ammonia level if
indicated.
• Consider liver biopsy at 2 years after transplantation in
patients who had bridging ﬁbrosis before transplantation
• Consider liver biopsy at 2 years for patients who had
hepatitis B (HBAg positive) or HCV before transplantation
• Refer patients who have HCV/hepatitis B HB infection to
gastroenterologist/infectious disease specialist for
consideration of antiviral therapy
Lung • Evaluate PFTs at 3, 6, and 12 months and then yearly
for 2 years (TLC, FEV1, FVC, DLCO).
• Consider annual PFTs for patients with early compromise or
if cGVHD until immunosuppressive medications have been
stopped
• Patients with new-onset or worsening PFTs should be
referred to a pulmonologist
• Consider echocardiography with evaluation of tricuspid
regurgitation jet velocity to rule out pulmonary
hypertension at 1 year, then as clinically indicated
• Measure pulmonary arterial pressure if tricuspid
regurgitation jet velocity > 3 m/s to conﬁrm pulmonary
hypertension
• Patients with pulmonary hypertension should be referred to
a pulmonologist
• Evaluate PFTs at 3, 6, and 12 months and then yearly
for 2 years (TLC, FEV1, FVC, DLCO).
• Consider annual PFTs for patients with early compromise or
if cGVHD until immunosuppressive medications have been
stopped
• Patients with new-onset or worsening PFTs should be
referred to a pulmonologist
• Consider echocardiography with evaluation of tricuspid
regurgitation jet velocity to rule out pulmonary
hypertension at 1 year, then as clinically indicated
• Measure pulmonary arterial pressure if tricuspid
regurgitation jet velocity > 3 m/s to conﬁrm pulmonary
hypertension
• Patients with pulmonary hypertension should be referred to
a pulmonologist
(Continued on next page)
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Table 1
(continued)
Organ/System Thalassemia SCD
Nervous system • Continue anticonvulsant therapy as needed if risk
factors—hypertension, calcineurin inhibitors
• MRI of the brain at 1-2 years post-transplant in patients
with CNS disease pretransplant and then as clinically
indicated for patients who had neurotoxicity (PRES or non-
PRES brain lesions).
• Refer patients if continued neurotoxicity and seizure
disorder to neurologist
• Consider age-appropriate neurocognitive evaluation
at 1 year and continue every 2 years
• Continue anticonvulsant therapy as needed if risk
factors—hypertension, calcineurin inhibitors
• Consider brain MRA/MRI at 1 and 2 years after HCT and
then every 2 years as clinically indicated in patients with a
history of stroke or moyamoya pretransplant.
• MRI at 1-2 years post-transplant in patients with PRES or
other neurotoxicity during transplant
• Consider age-appropriate neurocognitive evaluation at 1 year
and continue every 2 years if neurotoxicity a complication
• Refer patients if continued neurotoxicity and seizure
disorder to neurologist
Renal • Monitor renal function until patient off calcineurin inhibitor
or other nephrotoxic treatment and yearly for 2 years (BUN,
creatinine, electrolytes, GFR or 24-hour creatinine
clearance)
• Consider urine analysis for cells and proteinuria and renal
ultrasound at 1 year, then as clinically indicated
• Monitor renal function until calcineurin inhibitor and other
nephrotoxic therapy is discontinued and yearly
for 2 years (BUN, creatinine, electrolytes, GFR or 24-hour
creatinine clearance)
• Consider urinalysis for cells and proteinuria and renal
ultrasound at 1 year, then as clinically indicated
• Consider microalbuminuria testing annually after HCT
for 2 years
• Monitor blood pressure annually
Gastrointestinal • Consider gastroduodenoscopy or colonoscopy in patients
with unexplained diarrhea, malabsorption, or weight loss to
evaluate for cGVHD
• Consider gastroduodenoscopy or colonoscopy in patients
with unexplained diarrhea, malabsorption ,or weight loss to
evaluate for cGVHD
Ophthalmology • Consider evaluations at 1 year and 2 years, then as needed
• Yearly retinal exam in patients receiving iron chelation
therapy
• Consider evaluations at 1 year and 2 years, then as needed
• Yearly retinal exam in patients receiving iron chelation
therapy or if sickle retinopathy
Audiology
Dental
Thyroid • Thyroid function tests (TSH, free T4) at 6 months, 1 year,
then annually through 5 years
• Refer patients with abnormal thyroid tests to
endocrinologist for treatment
• Consider thyroid function tests (TSH, free
T4) at 6 months, 1 year, then yearly
• Refer patients with abnormal thyroid tests to
endocrinologist for treatment
Diabetes mellitus • Consider fasting glucose and GTT at the 1-year follow-up if
there is signiﬁcant iron overload or after steroid therapy is
discontinued if applicable; continue as indicated
• Consider fasting glucose and GTT at the 1-year follow-up if
there is signiﬁcant iron overload or after steroid therapy is
discontinued if applicable; continue as indicated
Gonads • Yearly physical examination; track Tanner progression;
gonadal hormones and gonadotropin levels when age
appropriate
• Total and free testosterone, LH, and FSH in males ≥ 11 years
of age, yearly for 2 years, then as clinically indicated if
puberty delayed.
• Consider age-appropriate sperm analysis in male patients
• LH, FSH, anti-Mullerian hormone, and estradiol in female
patients ≥ 11 years of age, at 1 and 2 years post-HCT, then as
clinically indicated if puberty delayed
• Refer patients with evidence of pubertal delay, low
testosterone levels, or females with primary or secondary
amenorrhea to endocrinologist, gynecologist, or andrologist
for hormonal treatment
• Counsel regarding genetic transmission of disease
• Yearly physical examination; track Tanner progression;
gonadal hormones when age appropriate
• Consider total and free testosterone, LH, and FSH in
males ≥ 11 years of age, yearly for 2 years, then as clinically
indicated if puberty delayed.
• Consider age-appropriate sperm analysis in male patients
• Consider LH, FSH, anti-Mullerian hormone, and estradiol in
female patients ≥ 11 years of age, at 1 and 2 years post-HCT,
then as clinically indicated
• Refer patients with evidence of pubertal delay, low
testosterone levels or females with primary or secondary
amenorrhea to endocrinologist, gynecologist, or andrologist
for hormonal treatment
• Counsel regarding genetic transmission of disease
Growth • Evaluate height, weight, and body mass index at 6 months
and then yearly
• Monitor every 6 months if growth velocity plateaus so
intervention can be planned as needed
• Assess hormone levels for short stature (IGF-1, IGF-BP3) and
bone age if within growth period by age
• Refer patients with growth retardation to endocrinologist to
discuss growth hormone treatment
• Evaluate height, weight, and body mass index at 6 months,
and then yearly
• Monitor every 6 months if growth velocity plateaus so
intervention can be planned as needed
• Assess hormone levels for short stature (IGF-1, IGF-BP3) and
bone age if within growth period by age
• Refer patients with growth retardation to endocrinologist to
discuss growth hormone treatment
Bone health • Vitamin D (25-OH) level and bone mineral density
evaluation for all patients at 1 year after HCT and
subsequently as indicated
• Patients with osteopenia and/or osteoporosis should receive
vitamin D and calcium supplementation
• Consider MRI of the joints to evaluate for avascular necrosis
in symptomatic patients on steroid therapy (cGVHD)
• Consider referral to endocrine services for patients with
osteoporosis
• Vitamin D (25-OH) level and bone mineral density
evaluation for all patients at 1 year after HCT and
subsequently as indicated
• Patients with osteopenia and/or osteoporosis should receive
vitamin D and calcium supplementation
• Consider MRI of the joints to evaluate for avascular necrosis
in symptomatic patients on steroid therapy (cGVHD)
• Consider referral to endocrine services for patients with
osteoporosis
Spleen function • Consider liver spleen scan and/or pitted RBC count
Engraftment/
chimerism
• If full donor chimerism present at 100 days, evaluate yearly
for 2 years.
• If chimerism is mixed, consider evaluation every 3-
6 months for 2 years; if stable, yearly thereafter
• Evaluation of myeloid chimerism preferable if available
• Can monitor hemoglobin level in lieu of chimerism and
evaluate chimerism if microcytic anemia
• If full donor chimerism present at 100 days, evaluate yearly
for 2 years.
• If chimerism is mixed, consider evaluation every 3-
6 months for 2 years; if stable, yearly thereafter
• Evaluation of myeloid chimerism preferable if available
• Consider hemoglobin electrophoresis evaluation yearly if
chimerism stable
(Continued on next page)
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pregnancy [21]. Transplanted patients should be advised that
despite having a normal hemoglobin level after HCT, the thal-
assemia genes in the germline are transmissible.
SCD TRANSPLANT-SPECIFIC FOLLOW-UP
The decision to pursue HCT for SCD is based on an as-
sumption that physical symptoms and/or ongoing organ
damage, including pulmonary or neurologic complications,
can be stabilized or even improved with no further deteri-
oration of organ function or SCD symptoms in the long-
term. If organ damage is reversible and symptoms are resolved
after HCT, these improvements should translate into a better
health-related quality of life (HRQOL) [22,23]. Splenic func-
tion in SCD, for example, may recover in most young
transplant recipients (<15 years old) and even in some older
individuals, especially in the absence of chronic GVHD [24].
Early pulmonary or neurologic complications may be revers-
ible to a variable extent [25]. Post-HCT follow-up is directed
at establishing and tracking the positive and negative effects
of HCT on sickle vasculopathy as expressed in target organs.
It is very likely that the inﬂammatory milieu and
pre-existing organ injury, which are common features of treat-
ing patients with severe SCD by HCT, predispose to transplant-
related complications. These include sickle nephropathy and
the development of hypertension during calcineurin inhib-
itor administration, hypogonadism, and the increased risk of
GVHD in older SCD recipients.
Target organs and SCD-related complications that should
bemonitored before and after HCT include the CNS (ischemic
or hemorrhagic infarcts, vasculopathy, atrophy, susceptibility
to posterior reversible encephalopathy syndrome, decline in
cognitive function), cardiopulmonary complex (pulmonary in-
suﬃciency, particularly restrictive pulmonary disease,
pulmonary hypertension), chronic pain, renal complications
(impairedglomerularﬁltrationandurinaryconcentratingability,
renal insuﬃciency, hypertension), sickle retinopathy, pria-
pism, gonadal dysfunction, RBC allo-immunization and post-
HCT transfusionmanagement, iron-related complications, and
splenic function. Long-term follow-up guidelines recom-
mended for identiﬁcation and monitoring of SCD-speciﬁc
complications and interventions are shown in Table 1.
NEUROCOGNITIVE FOLLOW-UP
CNS impairments in SCD can be subtle or overt, and
neurocognitive assessments can deﬁne important function-
al CNS domains. Because the plasticity of pre-existing CNS
damage is uncertain, these tests also measure the effect of
HCT itself on cognitive function. An informal survey at the
Pediatric Blood and Marrow Transplant Consortiummeeting
revealed that reliable access to systematic neuropsychologi-
cal evaluations was limited and often exacerbated by
insurance and other psychosocial barriers. Thus, we offer the
following operator- and nonoperator-dependent options for
neuropsychological assessment after HCT. If a skilled neu-
ropsychologist is available to participate in standard clinical
care, we recommend they refer to the PhenX SCD website
(https://www.phenxtoolkit.org/index.php?pageLink=about
.scd). Some but not all PhenX protocols are also available in
Spanish and Chinese languages. PhenX measures are peri-
odically updated to facilitate appropriate neurocognitive
studies in speciﬁc subgroups. This toolkit, developed by he-
moglobinopathy experts, followed a consensus process with
input from the scientiﬁc community. Selecting PhenX tests
that are clearly deﬁned, well established, low burden, repro-
ducible, and easily available guided the development of these
guidelines. Measures that had relevance across popula-
tions, were previously used in reference studies, and were
accepted by the research community made ideal post-HCT
comparators. Based on our knowledge of prevalent cogni-
tive deﬁcits in children with SCD, we recommend
measurements of the domains listed in Table 2.
If neurocognitive function evaluation is not practical
because of inadequate resources, a low-cost, low-burden al-
ternative is available through the National Institutes of Health
(NIH) Toolbox (http://www.healthmeasures.net/resource
-center/nih-toolbox-ipad-app) for cognitive measures. Proof
Table 1
(continued)
Organ/System Thalassemia SCD
cGVHD • Evaluate every month while receiving immunosuppression
• Evaluate every 3 months for 2 years after stopping
immunosuppression and as clinically indicated thereafter
• Evaluate every month when on immunosuppression
• Evaluate every 3 months off immunosuppression
until 2 years and as clinically indicated thereafter
Quality of life • Evaluate QOL in age-appropriate fashion at 1 year and as
needed—education, social life, activity (children),
employment, earning capacity, independence (adults)
• Track patient-reported
outcomes (www.healthmeasures.net)
• Evaluate pain symptoms and medication use at each clinic
visit
• Evaluate QOL in age-appropriate fashion at 1 year and as
needed—education, social life, activity (children),
employment, earning capacity, independence (adults)
• Track patient-reported
outcomes (www.healthmeasures.net)
Healthcare
utilization
• Consider tracking hospital admissions before, during, and
after recovery from HCT
• Track hospital admissions before, during, and after recovery
from HCT
Nutrition and
metabolic function
• Evaluate yearly—fasting lipid proﬁle, fasting glucose, blood
pressure, BMI, waist circumference
• Evaluate fasting lipid proﬁle, fasting glucose, blood
pressure, BMI, waist circumference yearly
Screening for
malignancy
• As indicated in age-appropriate fashion (skin, thyroid,
breast, colon, prostate, cervix, testes)
• As indicated in age-appropriate fashion (skin, thyroid,
breast, colon, prostate, cervix, testes)
We recommend yearly post-HCT follow-up for the ﬁrst 5 years. Subsequent transplant-related follow-up is recommended once every 2-3 years for the pa-
tient’s lifetime. ASBMT indicates American Society for Blood and Marrow Transplantation; EBMT, European Society for Blood and Marrow Transplantation;
cGVHD, chronic GVHD; PCN, penicillin; MRI, magnetic resonance imaging; GGT, γ-glutamyl transferase; PT, ; PFT, pulmonary function tests; TLC, total lung
capacity; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity of carbon monoxide; PRES, posterior reversible leu-
koencephalopathy syndrome; MRA, ; BUN, blood urea nitrogen; GFR, glomerular ﬁltration rate; TSH, thyroid-stimulating hormone; FSH, follicl- stimulating
hormone; LH, luteinizing hormone; GTT, glucose tolerance test; IGF, insulin-like growth factor; BMI, body mass index; vitamin D (25-OH), vitamin D (25
hydroxycholecalciferol).
* Serum ferritin is an acute phase reactant. It will be elevated in inﬂammatory conditions such as GVHD and is not a reliable indicator of iron over load in
that setting.
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of qualiﬁcation to access cognitive assessment is required. In
a clinical trial, a physician, psychologist, or healthcare pro-
vider with experience and/or training in this assessment can
obtain access for a small fee. The investigator can access tests
as an tablet application and oversee training with the appli-
cation. Videos for training are available online (http://www
.healthmeasures.net/NIH_Toolbox_iPad_e-learning/story
_html5.html). In-person training is available from the
HealthMeasures group. We recommend that clinical trial par-
ticipants complete assessments from the NIH Toolbox
Cognition Domain [26] using the NIH Toolbox tablet appli-
cation as shown in Table 3. Executive function, attention,
working memory, and processing speed can be assessed. In
addition, the battery includes 2 tests of crystalized abilities
(oral reading and vocabulary) as an estimate of pretransplant
functioning for comparison purposes. It takes approximate-
ly 35 minutes to complete the cognitive tests. Additional
research instruments that are relatively low burden but in-
formative include true measures of intelligence such as an
abbreviatedWechsler Abbreviated Scale of Intelligence, Second
Edition, which takes approximately 15 minutes to adminis-
ter and can be a serial reference point for intelligence. In a
small SCD cohort, intelligence quotients improved at 3 and
5 years post-HCT [35]. We caution that meaningful evalua-
tion depends on the maintenance of inter- and intrapatient
consistency in testing. Additional effort may be necessary to
accomplish testing because compliance may be challenging.
HCT-RELATED COMPLICATIONS
HCT-related complications that require long-term follow-
up after HCT for hemoglobinopathies include monitoring and
management of mixed donor–host hematopoietic chime-
rism, complications of chronic GVHD and treatment, immune
reconstitution and susceptibility to infections, and awareness/
screening for malignant transformation after exposure to
transplant conditioning regimens and immunosuppression
[3]. Mixed chimerism is common after HCT for hemoglobin-
opathy, presumably because of recipient immune competence
[36,37]. Although early mixed chimerism (within 2 years of
HCT) can be a dynamic phenomenon with a risk of graft re-
jection and disease recurrence, latemixed chimerism > 2 years
post-HCT (involving 10% to 15% of patients) is a more stable
phenomenon, and graft rejection is rare [38]. Stable mixed
chimerism usually generates the donor hemoglobin pheno-
type and is not distinguishable from full donor chimerism,
with regard to clinical beneﬁt [39].
The percentage of myeloid donor engraftment necessary
to maintain a functioning graft in hemoglobinopathy pa-
tients is not known, but 1 recent publication reported ≥ 20%
donor chimerismwas necessary for a curative effect [37,40,41].
In contrast, a donor chimerism level of 12% has been re-
ported to control SCD symptoms and was curative [42]. In
HCT for SCD from a donor with trait, if the hemoglobin S level
increases > 50%, disease recurrence follows. GVHD manifes-
tations are similar to those in patients with malignant
disorders, and incidence and severity vary according to the
graft source, HLA compatibility, and patient age [43]. De-
pending on its severity, chronic GVHD can negatively affect
long-term quality of life and requires monitoring and inter-
vention for control [44,45]. The incidence of malignant
disorders after HCT for thalassemia is <10 per 100,000 per
year and does not appear to be higher than in patients with
β-thalassemia major that are not transplanted [46,47]. The
incidence of malignancy after HCT for SCD is unclear and
should be monitored long term.
GONADAL FUNCTION AND FERTILITY PRESERVATION
Two forms of gonadal insuﬃciency can occur after HCT
in childhood: hypogonadotropic hypogonadism due to pitu-
itary iron overload and hypergonadotropic hypogonadism due
to gonadal damage from conditioning chemotherapy. Hor-
monal function in prepubertal boys is usually better preserved
than fertility because Leydig cells are less sensitive to con-
ditioning agents compared with spermatogonial cells [48,49].
Hormonal function and fertility are equally impaired in pre-
pubertal girls, and ovarian insuﬃciency is very common after
HCT postpuberty, particularly after exposure to myeloablative
busulfan [50]. Baseline gonadal function (Tanner staging,
Table 2
Recommended Measures of Cognition for Children with SCD
Domain Age Range Measure
Intelligence 6-16 years 11 months Wechsler Intelligence Scale for Children, Fifth Edition
16-90 years Wechsler Adult Intelligence Scale, Fourth Edition
If age range spans 6 years through adulthood Wechsler Abbreviated Scale of Intelligence, Second Edition
Sustained and selective attention 8 years old and older Conners Continuous Performance Test, 3rd Edition
Working memory 5-16 years Children’s Memory Scale
Executive function 5-18 years Behavior Rating Inventory of Executive Function
Parent reported
18 years and older Trail Making Test A and B
Adaptive behavior Any age Vineland Adaptive Behavior Scales, Second Edition
Parent reported for child
Table 3
Tests of Cognition using the NIH Toolbox
Type of Ability Validated Assessment Cognitive Function Addressed
Crystallized measures Picture Vocabulary Test [27,28] Intellectual achievement, demonstrated largely through vocabulary
and general knowledgeOral Reading Recognition Test [27,28]
Fluid measures Picture Sequence Memory Test [29,30] Episodic memory
Pattern Comparison Processing Speed Test [31,32] Processing speed
List Sorting Working Memory Test [31,32] Working memory
Flanker Inhibitory Control and Attention Test [33,34] Executive function/inhibitory control
Dimensional Change Card Sort Test [33,34] Executive function/cognitive ﬂexibility
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gonadotropin and hormone levels) should be assessed in all
patients who are 11 years of age and older pre-HCT. After
transplant, annual assessments of pubertal development,
sexual, and reproductive function is recommended based on
accelerated impairment after exposure to conditioning regi-
mens (Supplemental Table S1). This includes luteinizing
hormone, follicle-stimulating hormone, anti-Mullerian
hormone, and estradiol levels in females and follicle-
stimulating hormone, luteinizing hormone, and earlymorning
testosterone levels in males who are 11 years of age and older.
Evidence of abnormal pubertal timing or gonadal dysfunc-
tion should prompt early referral to an appropriate service
such as endocrinology, gynecology, urology, and/or repro-
ductive medicine.
Depending on the transplant method used and the age of
the recipient, individualized discussion about the risks of
gonadal dysfunction/infertility and options for fertility pres-
ervation are recommended pre-HCT. Postpubertal males can
pursue sperm cryopreservation. Patients considering off-
spring post-HCT should be informed about genetic
transmission of hemoglobinopathy to their children. Testicu-
lar tissue cryopreservation for ex vivo spermatogenesis and
in vitro fertilization is experimental [51-53]. Similarly,
postpubertal females can pursue options that include ovarian
protection techniques by hormonal suppression with
gonadotropin-releasing hormone agonists, embryo preser-
vation, and oocyte or ovarian tissue cryopreservation [54-58].
Some of these methods are only available on research pro-
tocols and often must be paid out of pocket.
ASSESSMENT OF HRQOL
HRQOL assessments after HCT are important tools for
assessing the beneﬁt of HCT in disorders that are not immi-
nently life-threatening and can guide clinical decision-
making. HRQOL assessments quantify broad nonorgan-
speciﬁc impacts of a disease-free state and are inﬂuenced
by transplant complications such as chronic GVHD. Al-
though nuanced measurement batteries that dive deeply
into the experiences of SCD and chronic GVHD are very
informative if completed, less-speciﬁc tools can be easier to
achieve repeatedly and matched across treatment options
with ease. Assessments pre-HCT, at 6 months, 12 months, 2
years, and yearly beyond if indicated can provide global
functional outcomes. Uniformity across clinical trials pro-
vides comparisons.
HRQOL assessment options used previously include the
Child Health Questionnaire or the Pediatric Quality of Life In-
ventory 4.0 [22,59]. A newer option is the Patient-Reported
OutcomesMeasurement Information System, a set of person-
centered measures that evaluates and monitors physical,
mental, and social health. Self and parent proxy measures are
available, and several of the domains like fatigue, pain in-
tensity, and peer relationships are particularly relevant to
children with SCD. The Patient-Reported Outcomes Mea-
surement Information System has been validated in multiple
populations with chronic conditions and is free to use
(http://www.healthmeasures.net/explore-measurement
-systems/promis) [60-65].
A complete pediatric evaluation of HRQOL includes both
child and parent reports in an age-dependent fashion. The
routine use of post-transplant HRQOL assessments irrespec-
tive of clinical trials, although challenging in busy clinical
practice settings, can be an important and useful long-term
outcome measure for providers, patients, and families.
ASSESSMENT OF HEALTHCARE UTILIZATION
The cost of healthcare in hemoglobinopathy patients in-
creases with age and frequency of complications [66].
Transplant costs, however, are highest when in the ﬁrst year
after the transplant is performed [67]. Hospital admissions
and health maintenance costs subsequently decrease in most
cases, unless there are signiﬁcant transplant-related com-
plications with prolonged hospitalizations. Tracking all costs
related to healthcare utilization post-HCT provides a com-
parison with the costs associated with supportive care in
hemoglobin disorders and has economic signiﬁcance for
payors and patients.
CONCLUSION
In summary, this report presents concise guidelines that
can be incorporated into clinical trial design and routine clin-
ical post-transplant follow-up care to track the impact of HCT
on patients with hemoglobin disorders. Standardizing
outcomemeasurements and ensuring global follow-up across
various treatment options such as supportive care, trans-
plant, and therapy with gene-modiﬁed cells can provide
objective information regarding the therapeutic interven-
tion, inform differences between treatment modalities, and
help with decision-making for patients, providers, and
families.
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